Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs
- 8 November 2005
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 316 (3), 1098-1106
- https://doi.org/10.1124/jpet.105.093393
Abstract
The purpose of the present study was to comparatively evaluate human HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. Various concentrations of 14 different drugs were initially evaluated in terms of their relative potency to block I(HERG) in stably transfected human embryonic kidney cells. Four general categories of drugs were identified: high-potency blockers (IC50 < 0.1 microM) included lidoflazine, terfenadine, and haloperidol; moderate-potency blockers (0.1 microM < IC50 < 1 microM) included sertindole, thioridazine, and prenylamine; low-potency blockers (IC50 > 1 microM) included propafenone, loratadine, pyrilamine, lovastatin, and chlorpheniramine; and ineffective blockers (IC50 > 300 microM) included cimetidine, pentamidine, and arsenic trioxide. All measurements were performed using similar conditions and tested acute drug effects only (<30 min of drug exposure per measurement). Since two of the drugs that were ineffective I(HERG) blockers, arsenic trioxide and pentamidine, have been associated with cardiac repolarization delays (QT interval lengthening) and torsades de pointes ventricular arrhythmias in patients, we chose to evaluate them further using the isolated perfused rabbit heart model. Neither arsenic trioxide nor pentamidine had any significant effect on QT intervals in this model, even at relatively high (micromolar) concentrations. Similar results were obtained for loratadine in this model. When the hearts were challenged with a known torsadogenic drug such as cisapride, significant QT lengthening was rapidly induced. These results demonstrate that arsenic trioxide and pentamidine are essentially devoid of direct acute effects on cardiac repolarization or inhibition of I(HERG).Keywords
This publication has 36 references indexed in Scilit:
- Pentamidine reduces hERG expression to prolong the QT intervalBritish Journal of Pharmacology, 2005
- Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (IKr) ChannelJournal of Cardiovascular Electrophysiology, 2004
- Drugs, hERG and sudden deathCell Calcium, 2004
- Prolongation of cardiac repolarization by arsenic trioxideBlood, 2002
- Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic LeukemiaAnnals of Internal Medicine, 2001
- Comparison of Tegaserod (HTF 919) and its Main Human Metabolite with Cisapride and Erythromycin on Cardiac Repolarization in the Isolated Rabbit HeartJournal of Cardiovascular Pharmacology, 1999
- Optical Mapping of Drug-Induced Polymorphic Arrhythmias and Torsade de Pointes in the Isolated Rabbit HeartJournal of the American College of Cardiology, 1997
- A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndromeCell, 1995
- Recurrent Ventricular Tachycardia Due to Pentamidine-Induced CardiotoxicityChest, 1988
- Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardiaThe American Journal of Cardiology, 1983